We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Dose-Dense Therapy in Aggressive Lymphoma

Expanded access is no longer available for this treatment.
ClinicalTrials.gov Identifier:
First Posted: August 17, 2007
Last Update Posted: August 17, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Arbeitsgemeinschaft medikamentoese Tumortherapie
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Condition Intervention
Lymphoma Drug: CEOP/IMVP-Dexa chemotherapy

Study Type: Expanded Access     What is Expanded Access?
Official Title: Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

Intervention Details:
    Drug: CEOP/IMVP-Dexa chemotherapy
    Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
Detailed Description:
Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • 18 and 70 years of age
  • Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified
  • Measurable disease
  • All stages

Exclusion Criteria:

  • Lymphoblastic or Burkitt histology
  • CNS-disease
  • HIV-positive
  • pregnant or lactating women
  • Pretreatment
  • Other malignancy
  • Concomitant diseases that forbid chemotherapy
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00517894     History of Changes
Other Study ID Numbers: NHL-5
First Submitted: August 15, 2007
First Posted: August 17, 2007
Last Update Posted: August 17, 2007
Last Verified: August 2007

Keywords provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Behavioral Symptoms